Intended for healthcare professionals


In brief

BMJ 2014; 348 doi: (Published 21 May 2014) Cite this as: BMJ 2014;348:g3416

AstraZeneca rejects Pfizer’s final takeover bid: The board of the UK drug company AstraZeneca has turned down what the US drug company Pfizer has said was its final takeover bid of £69bn (€85bn; $120m), saying that the bid “undervalues” the UK company and its “attractive prospects.” Leif Johansson, AstraZeneca’s chairman, said that Pfizer’s approach was driven by corporate financial benefits and tax minimisation rather than a “strategic, business, or value case.” MPs have raised concerns that the takeover would have …

View Full Text

Log in

Log in through your institution


* For online subscription